Serial Number:
85499819
Mark:
ROADMAP RANDOMISED OLMESARTAN AND DIABETES MICROALBUMINURIA PREVENTION STU
Status:
Cancelled-Section 8
Status Date:
03-13-2020
Filing Date:
Registration Number:
4378430
Registration Date:
08-06-2013
Pharmaceutical preparations for the treatment and prevention of cardiovascular disease, atherosclerosis, diabetic nephropathy, stroke, heart attack, hypercholesterolemia, dyslipidemia, anemia, blood disorders, diabetes, thyroid function disease, cancer, oncological disease, metastasis, autoimmune disease, allergy, bacterial infection, viral infection, fungal infection, inflammation, musculoskeletal disorders, pain, osteoporosis, Alzheimer's disease, obesity, anorexia, urinary and kidney disease, respiratory disease, gastrointestinal disease; vaccines; diagnostic reagents and contrast media for medical use Medical and scientific research, namely, conducting of clinical studies and trials of pharmaceuticals; providing medical and scientific research information in the field of clinical trials
Mark Description:
The mark consists of the stylized wording "ROADMAP RANDOMISED OLMESARTAN AND DIABETES MICROALBUMINURIA PREVENTION STUDY" in white with a black globe with white continents and two blue arrows and one red arrow, all on a blue rectangle.
Class:
Scientific and technological services
Type of Mark:
Trademark
Published for Opposition Date:
05-21-2013
Mark Drawing Status:
Design plus Words, Letters, and/or Numbers
Abandon Date:
N/A
Business Name:
WENDEROTH LLP
Correspondent Name:
